Business Wire

Estée Lauder Launches Emerging Leaders Fund to Advance the Next Generation of Women Redefining Leadership

Share

Estée Lauder, the flagship brand of The Estée Lauder Companies Inc., is proud to announce the launch of the Estée Lauder Emerging Leaders (ELEL) Fund, a charitable fund under The Estée Lauder Companies Charitable Foundation. The ELEL Fund’s mission is to redefine leadership by supporting a new generation of emerging women leaders and challenging the gender stereotypes of leadership. The Fund will support global organizations that provide opportunities for leadership development, cultivate supportive communities and advocate for emerging leaders who have a daring vision for change.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005425/en/

Estée Lauder has made an initial $1MM investment into the ELEL Fund which will support mission-aligned organizations. Vital Voices, a global nonprofit that invests in women leaders, has been selected as the inaugural program partner of the ELEL Fund, with the program commencing in July 2022. Additional grants by the ELEL Fund will be announced in the coming year.

Global Leadership and Gender Report by Estée Lauder
To gain a deeper understanding of perceptions of leadership and gender bias around the world, the Estée Lauder brand commissioned Glocalities, an international market research agency, for a global study of more than 5,700 men and women across 11 countries. The research revealed that whilst there are still prevalent gender biases and stereotypes when it comes to leadership, both men and women value the same qualities in a leader - reliability, integrity and dedication - which are not attached to gender. However, while leadership qualities such as strength and determination are equally valued by both men and women they are more strongly associated with men. The study reveals the roadblocks and solutions for advancing gender-inclusive leadership.

Estée Lauder’s Legacy
As one of the leading prestige beauty brands in the world, Estée Lauder continues to be inspired by its founder, Mrs. Estée Lauder, and her belief in a woman’s infinite possibilities. The ELEL Fund will reinforce the brand’s commitment to women’s advancement by addressing some of the gender-based biases uncovered in the research and shifting the perception of leadership.

“The 75-year legacy of the Estée Lauder brand shows what one visionary woman can achieve,” said Stéphane de La Faverie, Group President, The Estée Lauder Companies and Global Brand President, Estée Lauder & AERIN Beauty. “Through the work of the Estée Lauder Emerging Leaders Fund and its program partners, we will champion women to contribute and lead in their workplaces and communities. We want to redefine what it means to be a leader and what it takes to lead. We want to see more women like Mrs. Estée Lauder in the world.”

The VV Visionaries Leadership Program in partnership with the ELEL Fund
The Estée Lauder Emerging Leaders Fund selected Vital Voices, a global nonprofit that invests in women leaders who are taking on the world’s greatest challenges, as its first official program partner and grant recipient. With the shared mission of advancing women and redefining leadership, the ELEL Fund and Vital Voices have built a custom online and offline leadership development program for emerging leaders globally. Program participants will join the Vital Voices community of over 20,000 women across 184 countries, which includes Estée Lauder Global Changemaker, Amanda Gorman. Applications are now open for the first and second cohort and can be accessed at www.vitalvoices.org/program/visionaries.

“At Vital Voices we have seen that women lead differently, and that difference is precisely what our world needs,” said Alyse Nelson, Vital Voices President and CEO. “Our partnership with the Estée Lauder Emerging Leaders Fund will identify emerging leaders with a bold vision for positive change and provide them with the skills, network and resources they need to make that vision a reality.”

To learn more about the ELEL Fund, visit esteelauder.com.

Follow @esteelauder and #LeadYourWay hashtag to join the conversation.

About Estée Lauder
Estée Lauder is the flagship brand of The Estée Lauder Companies Inc. Founded by Estée Lauder, one of the world’s first female entrepreneurs, the brand today continues her legacy of creating innovative, sophisticated, high-performance skincare and makeup products and iconic fragrances – all infused with a deep understanding of women’s needs and desires. Today, Estée Lauder engages with customers in more than 150 countries and territories around the world and across dozens of touch points – from in-store to digital. And each of these relationships consistently reflects Estée’s powerful and authentic woman-to-woman point of view. Follow @esteelauder on Instagram, Facebook, Twitter, TikTok and YouTube.

About The Estée Lauder Emerging Leaders Fund
The Estée Lauder Emerging Leaders Fund is a charitable fund of The Estée Lauder Companies Charitable Foundation, a U.S. based charity incorporated and tax exempt in the United States of America.

About Vital Voices
Driven by the universal truth that women are the key to progress in their communities and that nations can’t move forward without women in leadership positions, Vital Voices Global Partnership has directly invested in more than 20,000 changemakers across 184 countries and territories over the last 24 years. It has provided early support for leaders who went on to become Nobel Peace Prize Laureates, U.S. Youth Poet Laureates, Prime Ministers, award-winning innovators, pioneering human rights defenders, and breakthrough social entrepreneurs, including Amanda Gorman, Malala Yousafzai, and more. Serving as a “venture catalyst,” the non-profit identifies leaders with a daring vision for change and partners with them to make that vision a reality. It provides connections, increased capacity, a peer network, financial support, skills training, and increased visibility for their work, which ranges from gender-based violence to the climate crisis, economic inequities. Follow @vitalvoices on Instagram, Facebook, Twitter, LinkedIn, and YouTube.

ELB-B

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR Contacts

Tara Connaughton, Estée Lauder, tconnaug@estee.com
Stephanie Katz, Estée Lauder, skatz@estee.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of